Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn

Table of Contents

January 01, 1990; Volume 37,Issue 1
  • You have access
    Molecular cloning and expression of a dopamine D2 receptor from human retina.
    T M Stormann, D C Gdula, D M Weiner and M R Brann
    Molecular Pharmacology January 1990, 37 (1) 1-6;
  • You have access
    Rat homologs of the Drosophila dunce gene code for cyclic AMP phosphodiesterases sensitive to rolipram and RO 20-1724.
    J Henkel-Tigges and R L Davis
    Molecular Pharmacology January 1990, 37 (1) 7-10;
  • You have access
    Evidence of DNA topoisomerase II-dependent mechanisms of multidrug resistance in P388 leukemia cells.
    P De Isabella, G Capranico, M Binaschi, S Tinelli and F Zunino
    Molecular Pharmacology January 1990, 37 (1) 11-16;
  • You have access
    Interaction between DPI 201-106 enantiomers at the cardiac sodium channel.
    G Wang, M Dugas, I Ben Armah and P Honerjäger
    Molecular Pharmacology January 1990, 37 (1) 17-24;
  • You have access
    Bromobenzene-mediated alteration in activity and electrophoretic pattern of biliverdin reductase variants in rat kidney.
    T J Huang and M D Maines
    Molecular Pharmacology January 1990, 37 (1) 25-29;
  • You have access
    Alpha 1-adrenergic stimulation and beta 2-adrenergic inhibition of DNA synthesis in vascular smooth muscle cells.
    T Nakaki, M Nakayama, S Yamamoto and R Kato
    Molecular Pharmacology January 1990, 37 (1) 30-36;
  • You have access
    Chronic agonist exposure induces down-regulation and allosteric uncoupling of the gamma-aminobutyric acid/benzodiazepine receptor complex.
    D J Roca, I Rozenberg, M Farrant and D H Farb
    Molecular Pharmacology January 1990, 37 (1) 37-43;
  • You have access
    Amplification of cyclic AMP generation reveals agonistic effects of certain beta-adrenergic antagonists.
    J R Jasper, M C Michel and P A Insel
    Molecular Pharmacology January 1990, 37 (1) 44-49;
  • You have access
    Affinity labeling of mu opioid receptors by sulfhydryl alkylating derivatives of morphine and morphinone.
    J M Bidlack, D K Frey, R A Kaplan, A Seyed-Mozaffari and S Archer
    Molecular Pharmacology January 1990, 37 (1) 50-59;
  • You have access
    Post soluble binding to the leukotriene D4 receptor from guinea pig lung membranes.
    S Mong and H M Sarau
    Molecular Pharmacology January 1990, 37 (1) 60-64;
  • You have access
    Nonadrenergic [3H]idazoxan binding sites are physically distinct from alpha 2-adrenergic receptors.
    M C Michel, J W Regan, M A Gerhardt, R R Neubig, P A Insel and H J Motulsky
    Molecular Pharmacology January 1990, 37 (1) 65-68;
  • You have access
    Irreversible loss of [3H]forskolin binding sites in human platelets by alpha-haloacetyl analogs of forskolin.
    A Laurenza, D Morris and K B Seamon
    Molecular Pharmacology January 1990, 37 (1) 69-74;
  • You have access
    Central 5-hydroxytryptamine receptor-linked protein kinase C translocation: a functional postsynaptic signal transduction system.
    H Y Wang and E Friedman
    Molecular Pharmacology January 1990, 37 (1) 75-79;
  • You have access
    Effect of inorganic calcium channel blockers on dihydropyridine binding to cardiac sarcolemma.
    W P Schilling, M C Zaher and D Rampe
    Molecular Pharmacology January 1990, 37 (1) 80-89;
  • You have access
    Thymopoietin, a thymic polypeptide, regulates nicotinic alpha-bungarotoxin sites in chromaffin cells in culture.
    M Quik, R Afar, S Geertsen, T Audhya, G Goldstein and J M Trifaró
    Molecular Pharmacology January 1990, 37 (1) 90-97;
  • You have access
    Convulsant and anticonvulsant cyclopentanones and cyclohexanones.
    K D Holland, D K Naritoku, A C McKeon, J A Ferrendelli and D F Covey
    Molecular Pharmacology January 1990, 37 (1) 98-103;
  • You have access
    Regulation of tyrosine hydroxylase activity in pheochromocytoma PC-12 cells by bradykinin.
    H Houchi, J M Masserano, J F Bowyer and N Weiner
    Molecular Pharmacology January 1990, 37 (1) 104-110;
  • You have access
    Detection of site-specific binding and co-binding of ligands to human serum albumin using 19F NMR.
    B G Jenkins and R B Lauffer
    Molecular Pharmacology January 1990, 37 (1) 111-118;
  • You have access
    Effects of testosterone and growth hormone treatment on hepatic microsomal P450 expression in the diabetic rat.
    K E Thummel and J B Schenkman
    Molecular Pharmacology January 1990, 37 (1) 119-129;
  • You have access
    Effects of 4-alkyl analogues of 3,5-diethoxycarbonyl-1,4-dihydro-2,4,6-trimethylpyridine on hepatic cytochrome P-450 heme, apoproteins, and catalytic activities following in vivo administration to rats.
    D S Riddick, S S Park, H V Gelboin and G S Marks
    Molecular Pharmacology January 1990, 37 (1) 130-136;
Back to top
PreviousNext

In this issue

Molecular Pharmacology
Vol. 37, Issue 1
1 Jan 1990
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts
  • Most Cited
  • Most Read
Loading
  • SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7
  • The G-Protein-Coupled Receptors in the Human Genome Form Five Main Families. Phylogenetic Analysis, Paralogon Groups, and Fingerprints
  • Pharmacological Properties of Y-27632, a Specific Inhibitor of Rho-Associated Kinases
  • Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
  • The Orphan Human Pregnane X Receptor Mediates the Transcriptional Activation of CYP3A4 by Rifampicin through a Distal Enhancer Module
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics